AstraZeneca
  • Bookmark This Page
  • Print This Page
  • Share with a Friend
Change Text Size
Change Text Size
Change Text Size
Change Text Size
Change Text Size

Help my patients and their parents

Demonstrated Safety

Asthma can be challenging for patients and their families.

AstraZeneca shares your commitment to improving pediatric asthma care and offers practical information and links to help your patients and their families get the information and assistance they need.

  • The AsthmaKidCare™ program is a free circle of support that offers your patients’ caregivers a wealth of ideas and information about asthma. The program provides informational newsletters and e-mails with medical advice, expert opinions, resources and encouragement that will assist them in understanding and treating their child’s asthma.

    Your patients' caregivers can join the AsthmaKidCare™ program online at www.asthmakidcare.com

  • At www.everydaykidz.com, parents can learn the basics about asthma and how to effectively treat and prevent symptoms. EVERYDAYKIDZ™ is an ongoing patient education program with multiple online features created specifically for children and their caregivers that are fun, free, and engaging

Other patient resources

Please choose a link for additional educational materials and health management resources for your patients:

  • Caregiver Insights
    Gain insight into your patients by viewing the results of polls conducted on the PULMICORT RESPULES Web site for consumers.
  • Asthma Screening Tool
    Use this form to help your patients tell you about their asthma symptoms.
  • Local Asthma Screenings & Events
    Link to current regional asthma patient screenings and other events of interest.
  • Custom Patient Information
    Select from a list of useful, educational asthma-related materials to compile a printable, customized document for each patient, which you can personalize with patient information.
  • Locate a Nebulizer
    Discover online resources for obtaining jet nebulizers.

Links to additional patient sites which may help your patients and their parents learn more about asthma:

Note: These Web sites are external to AstraZeneca. AstraZeneca does not possess editorial control of their content and no endorsement, expressed or implied, is intended.

“Next” Button
Learn about caregiver insights

Indication and Important Safety Information

PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children ages 12 months to 8 years.

PULMICORT RESPULES is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm.

Common adverse events reported in clinical trials, regardless of relationship to treatment, included respiratory infection, rhinitis, coughing, otitis media, viral infection, gastroenteritis, ear infection, oral thrush/candidiasis, and epistaxis.

Inhaled corticosteroids may cause a reduction in growth velocity. The long-term effect on final adult height is unknown.

PULMICORT RESPULES, like other inhaled corticosteroids, may impact the hypothalamic-pituitary-adrenal axis, especially in susceptible individuals, in young children, and in patients given high doses for prolonged periods.

Particular care is needed for patients who are transferred from systemically active corticosteroids to less systemically available corticosteroids, because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids (see WARNINGS in full Prescribing Information).

Patients taking immunosuppressant doses of corticosteroids should avoid exposure to infections such as chicken pox and measles.

[Please see accompanying full Prescribing Information (PDF).]